Stockreport

Acceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual Meeting

Acceleron Pharma Inc.  (XLRN) 
Last acceleron pharma inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.acceleronpharma.com/investor-relations
PDF – Updated results from MEDALIST Phase 3 trial show 47.1% of patients with anemia associated with myelodysplastic syndromes treated with luspatercept achieved red blood c [Read more]